Please login to the form below

Introduction to the manufacturing of biologics

The last decade has seen the rapid growth of biologics in the pharma market, making them a key sector to watch. With their growing popularity, it’s important to understand the opportunities and threats they present. Associate Consultant Ditte Funding takes us through how biologics are made, what makes them unique, and what it all means for pharma companies.
The last decade has seen the rapid growth of biologics in the pharmaceutical market, making them a key sector to watch in the coming years. Biopharma made up 22% of big pharma companies’ sales in 2013, with this number being expected to rise to 32% of sales by 2023. With the growing popularity of these products, it’s important to understand the opportunities and threats they present to pharma companies.

Associate Consultant Ditte Funding takes us through how biologics are made, what makes them unique, and what it all means for pharma companies.

What is a biologic?

Before looking at how to manufacture them, it’s important to first understand what a biologic is. The definition of a biologic isn’t always clear, and what’s considered a biologic is constantly being updated and tweaked as new products are introduced to market. However, the broad definition of a biologic is they are created by either a microorganism or a mammalian cell, and are large, complex molecules; the majority of which are proteins or polypeptidesExamples of biologics include blood or blood products, gene therapies, vaccines, and cell therapies.

There is a significant distinction that needs to be made between traditional small molecule pharmaceuticals (such as aspirin), and biopharmaceuticals. Biologics differ from small molecule drugs in their cost, production, administration, and clinical efficacy. Small molecule drugs are usually chemically synthesised, simple, and have a very well-defined structure. Whereas biologics, or large molecule drugs, are difficult to define and characterise. 

Biologics present great value, as they are highly specific molecules that tend to target more difficult to treat populations; it seems that biologics may become a primary tool for targeting hitherto untreatable diseases. However, in order for biologics to be widely used treatments in the future, they must be manufactured at the right cost and the right scale.


Download the full article from Blue Latitude Health




17th January 2017

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Understanding COVID-19 and varying responses across the globe
At the beginning of the COVID-19 Pandemic, Senior Account Executive Lauren Fernandes took a course at the London School of Hygiene and Tropical Medicine to better understand how the global response to the virus and to ensure we were best positioned to serve our clients during this challenging time. She shares the key learnings and why understanding the epidemiology of the disease is integral for fighting it.
Blue Latitude Health
Top 5 tips for a multi-indication product launch
Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.
Blue Latitude Health
If our patients are diverse, why are clinical trials so white?
Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.
Blue Latitude Health
Engaging physicians during COVID-19
COVID-19 has drastically changed the lives of healthcare professionals. They are emotionally and physically drained and under huge amounts of pressure. They also need pharma’s help. Senior Consultant Pany Koizi outlines five principles for engaging with physicians during the pandemic.
Blue Latitude Health
Fishawack Health adds market access and commercial strategy consultancy Skysis as part of its bold growth plans
Fishawack Health, the global healthcare communications agency, announces the acquisition of Skysis, a boutique consulting firm providing integrated market access and commercial strategy solutions based in the US.
Blue Latitude Health
Perspective: the patient edition
In this issue of Perspective magazine, we explore how the industry can place a greater emphasis on patient-centricity, and how pharmaceutical companies are working with patients across the product lifecycle to develop therapies that better serve their unmet needs.
Blue Latitude Health